Abbott Labs Stock Price, News & Analysis

Abbott's FreeStyle Libre® continuous glucose monitoring (CGM) technology has demonstrated groundbreaking results in reducing cardiovascular disease-related hospitalizations for diabetes patients. The REFLECT real-world studies show a 78% reduction in heart-related hospitalizations for Type 1 diabetes patients with prior severe low blood sugar episodes. For Type 1 diabetes patients with no prior cardiovascular disease history, hospitalizations decreased by 80%, while those with prior history saw a 49% reduction. The technology also showed similar benefits for Type 2 diabetes patients on insulin. This is particularly significant as diabetes affects approximately 589 million people globally, with diabetic patients being 2-4 times more likely to develop heart disease than non-diabetics. The findings suggest that Libre technology could lead to lower healthcare costs through reduced hospital admissions while helping patients better manage both their diabetes and cardiovascular health.

Cadrenal Therapeutics (NASDAQ: CVKD) reported its Q1 2025 financial results and corporate updates. Key highlights include: appointment of Dr. James Ferguson as Chief Medical Officer, a successful FDA Type D Meeting providing guidance for tecarfarin's Phase 3 trial, and a Collaboration Agreement with Abbott for the TECH-LVAD trial. The company completed technical transfer of tecarfarin manufacturing to a U.S. CDMO and conducted market research showing growth potential in the LVAD market. Financial results show R&D expenses of $1.7M (up from $0.6M in Q1 2024), G&A expenses of $2.3M (up from $1.1M), and a net loss of $3.8M. Cash position stands at $7.3M as of March 31, 2025, down from $10.0M at year-end 2024.

Abbott (ABT) and Real Madrid announced the creation of the 'Abbott Dream Team' program, seeking talented soccer players aged 18-19 across the U.S. The program will host tryouts in five major cities (Chicago, Dallas, Los Angeles, Philadelphia, and Washington, D.C.) from June 17 to July 24, 2025, with each location accepting up to 250 participants. Eleven selected players will travel to Madrid to train at Real Madrid's facilities and receive instruction from their coaches. American soccer legend Clint Dempsey will mentor the athletes. The program, part of the 'Beat Malnutrition' campaign, includes health and nutrition education from Abbott experts. Since 2022, the Abbott-Real Madrid partnership has provided over 67,000 hours of health education and screened 6,800 children for malnutrition risk in 12 countries.

MotoAmerica has become the first professional sports organization globally to implement Abbott's (NYSE: ABT) innovative blood test for concussion evaluation at race events. The i-STAT TBI test, which received FDA clearance in 2024, uses Abbott's portable i-STAT® Alinity® device to analyze whole blood samples and deliver results in just 15 minutes. The test measures two brain-specific biomarkers (UCH-L1 and GFAP) to help determine if a CT scan is needed following a suspected mild traumatic brain injury. This groundbreaking technology will be available at all MotoAmerica races in 2025, starting with the Michelin Raceway Road event in Atlanta (May 2-4). The test requires only a few drops of blood and provides objective data to assist healthcare professionals in making quick, informed decisions about rider safety and treatment needs.

Abbott has partnered with Epic to integrate data from its FreeStyle Libre continuous glucose monitoring (CGM) systems directly into Epic's electronic health record systems in the U.S. This first-of-its-kind integration allows data from users' LibreView accounts to automatically link to Epic's platform.

Through Epic's Aura software, over 575,000 U.S. healthcare providers serving 280 million patients will gain streamlined access to patients' glucose data within their existing workflows. The collaboration aims to enhance care efficiency by enabling providers to view glucose data before, during, and after patient consultations.

Key benefits include:

• Improved workflow efficiency for healthcare providers
• Seamless access to CGM data in patient charts
• Enhanced patient-provider collaboration
• More time for care management versus administrative tasks

Abbott plans to expand this model to other medical devices and connected care platforms in the future. Healthcare providers interested in updates can contact Abbott at Libre.Epic@abbott.com.

Abbott (NYSE: ABT) announced breakthrough results from its AVEIR™ Conduction System Pacing (CSP) acute clinical feasibility study, the world's first assessment of a leadless pacemaker delivering conduction pacing to the heart's left bundle branch area. The study demonstrated successful implantation of the AVEIR CSP leadless pacemaker technology.

Additionally, Abbott has initiated the ASCEND CSP pivotal clinical trial to evaluate their investigational CSP Implantable Cardioverter-Defibrillator lead, which will enroll up to 414 people across 70 global sites. The company received FDA Breakthrough Device Designations for both the AVEIR CSP leadless pacemaker system and the CSP ICD lead for left bundle branch area pacing (LBBAP).

Abbott's UltiPace™ Pacing Lead became the first FDA-approved stylet-driven lead indicated for left bundle branch area placement, marking significant progress in their cardiac rhythm management portfolio.

Abbott (NYSE: ABT) has revealed compelling 12-month data from its Volt CE Mark Study, demonstrating sustained benefits of the Volt™ PFA System for treating atrial fibrillation. The study, presented at the 2025 Heart Rhythm Society meeting, showed impressive results for both paroxysmal (PAF) and persistent AFib patients.

Key findings after 12 months include:

• 83.5% of PAF patients and 58.1% of PersAF patients remained arrhythmia-free
• Quality of life scores improved significantly from 64.1 to 88.1
• Only 2.7% of patients experienced primary safety endpoint events
• Zero patients suffered from common PFA therapy complications
• System achieved results with just 4.7 applications per vein on average

The Volt PFA System utilizes high-energy electrical pulses for targeted cardiac tissue treatment and can be administered under either light sedation or general anesthesia, offering procedural flexibility.

Abbott (NYSE: ABT) reported strong first-quarter 2025 results with reported sales growth of 4.0% and organic sales growth of 6.9%. First-quarter GAAP diluted EPS reached $0.76, while adjusted diluted EPS was $1.09, showing double-digit growth year-over-year.

Key financial metrics include a reported gross margin of 52.8% and adjusted gross margin of 57.1%, reflecting a 140 basis point increase. The company's operating margin stood at 16.3%, with adjusted operating margin at 21.0%, up 130 basis points.

Notable developments include: CE Mark approval for Volt™ PFA System, initiation of the TECTONIC trial for Coronary IVL System, and positive two-year data from TRILUMINATE™ trial for TriClip™ device. Abbott reaffirmed its full-year 2025 guidance, projecting organic sales growth of 7.5-8.5% and adjusted diluted EPS of $5.05-$5.25.

Abbott (NYSE: ABT) announced positive two-year data from its TRILUMINATE™ Pivotal trial for the TriClip™ transcatheter edge-to-edge repair (TEER) system, designed to treat tricuspid regurgitation (TR). The results, presented at ACC.25 and published in Circulation, demonstrate significant improvements over medical therapy.

Key findings after two years include:

• Significant reduction in heart failure hospitalizations (0.19 vs. 0.26 events/patient-year) in the treatment group
• 84% of TriClip patients achieved moderate or less TR grade versus 21% in control group
• Patients showed over 15-point improvement in quality of life scores (KCCQ)
• More than half of control group patients (142 of 241) crossed over to receive TriClip therapy, showing similar improvements

The data confirms TriClip as a safe and effective treatment option for TR patients who are not suitable for open-heart surgery, offering sustained benefits in reducing valve leakage and improving quality of life.